Table 3 Strategies to mitigate disparities in relapsed/refractory multiple myeloma.

From: Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

 

Individual advocacy

Interpersonal advocacy

Conventional therapies

Avoid IMiD avoidance: Consider Duffy-null status, requirements for future CAR-T candidacy, and more

Encourage patient co-management: Build bidirectional ties between primary oncologists and MM specialists to help identify optimized dosing regimens

IEC therapies

Build the patient’s trust: Explain the importance of trials & data collection and take the time to answer questions

Bring bsAbs back home: Partner with manufacturers, hospitals, payers, and academic centers to implement bsAbs at smaller practices

Supportive care

Screen for SDOH risk factors: Understand each patient’s risk of financial toxicity, food insecurity, and other challenges

Keep the primary in PCP: Promote longitudinal access to a primary care provider regardless of MM status or current line of therapy

  1. bsAb bispecific antibody, CAR-T chimeric antigen receptor T-cell therapy, IEC immune effector cell therapies, IMiD immunomodulatory imide drug, MM multiple myeloma, PCP primary care provider, SDOH social determinants of health.
Back to article page